Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

KALYDECO 150 MG

IVACAFTOR : 150 MG · DIN 02397412 · VERTEX PHARMACEUTICALS (CANADA) INCORPORATED

Health Canada status: MARKETED

What is KALYDECO?

KALYDECO 150 MG contains IVACAFTOR : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02397412, held by VERTEX PHARMACEUTICALS (CANADA) INCORPORATED, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 27-Nov-2012. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is KALYDECO used for?

Treatment of cystic fibrosis (CF) in patients aged 2 months and older with specific mutations (G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R, or R117H) in the CFTR gene.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

Product details and regulatory record

DIN02397412
Brand nameKALYDECO
Generic / active ingredientIVACAFTOR : 150 MG
ManufacturerVERTEX PHARMACEUTICALS (CANADA) INCORPORATED
Strength150 MG
Dosage formTABLET
Route of administrationORAL
SchedulePrescription
ATC codeR07AX02 IVACAFTOR
AHFS class48:14.12
BiosimilarNo
Health Canada statusMARKETED
Status date27-Nov-2012
Original market date2012-11-27 00:00:00

How is it administered?

Take orally approx. 12 hours apart with fat-containing food. Tablets: Swallow whole. Granules: Mix with 5 mL soft food/liquid, consume within 1 hour. Dosage depends on age and weight.

Included because it drives pack selection and wastage. Consult the monograph.

How is it stored and handled?

Not explicitly detailed in provided text (standard section 11 header present but content truncated).

How is it supplied?

Tablets: Blister pack (56) or HDPE bottle (60). Granules: 56-count carton containing unit dose packets.

Contraindications

Hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.

Warnings and precautions

Elevated transaminases (ALT/AST); monitor liver function. Risk of cataracts in pediatrics; baseline/follow-up exams recommended. Dizziness may affect driving/operating machinery.

What can be used instead?

Other Canadian products sharing ATC code R07AX02 IVACAFTOR. 5 of 5 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.

ProductStrengthFormManufacturerHealth Canada statusDIN
KALYDECO13.4 MGGRANULESVERTEX PHARMACEUTICALS (CANADA) INCORPORATEDMARKETEDDIN 02543451
KALYDECO25 MGGRANULESVERTEX PHARMACEUTICALS (CANADA) INCORPORATEDMARKETEDDIN 02519364
KALYDECO50 MGGRANULESVERTEX PHARMACEUTICALS (CANADA) INCORPORATEDMARKETEDDIN 02442612
KALYDECO75 MGGRANULESVERTEX PHARMACEUTICALS (CANADA) INCORPORATEDMARKETEDDIN 02442620

Who else supplies IVACAFTOR worldwide?

Nexara tracks national medicine registries and published price lists across multiple markets. IVACAFTOR appears in 23 registered pack listings across 2 markets, published on 2 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.

Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for KALYDECO

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Request a quote for KALYDECO

Health Canada Drug Product Database (DPD), DIN 02397412. Last reviewed 2026-09-08. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.